CION Ameerpet
"What type of lymphoma do I have?" is the question that shapes everything next. Your subtype is decided on tissue — through biopsy, immunophenotyping and molecular tests read against the WHO classification. This guide explains how it is done, and how CION's haematology team confirms it before any treatment.
Lymphoma is not one disease. It is a family of more than 60 distinct cancers of the lymphatic system, and the differences between them are enormous. Some are slow-growing and safely monitored for years; some are fast-growing but highly curable; a few need urgent, intensive treatment. That is why the very first job after a suspected lymphoma is not to start therapy — it is to identify the exact subtype. This process is called lymphoma classification, and it is the foundation of everything that follows.
Your subtype is decided on tissue, examined by a specialist haematopathologist, and named against the World Health Organization (WHO) classification that NCCN and ESMO both reference. A scan can show where disease is; a blood test can raise suspicion; but only the biopsy tissue can tell doctors whether you have, for example, Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), or a T-cell lymphoma. Getting this right — before treatment — is the single most important step in the whole journey.
This guide walks through each layer of the workup in plain language, so you understand what your team is doing and why the wait for a full result is worth it. For the bigger picture, see our Lymphoma hub, and when you are ready to plan care, Lymphoma Treatment in Hyderabad.
The World Health Organization classification of lymphoid tumours recognises more than 60 distinct lymphoma subtypes, each defined by the cell it arises from, its appearance, its surface markers and its genetics. This is why "lymphoma" alone is never a complete diagnosis — the named subtype is what determines treatment. (Source: WHO Classification of Haematolymphoid Tumours, 5th edition, as referenced in NCCN and ESMO lymphoma guidelines.)
No single test names a lymphoma. Doctors build the diagnosis in layers, each adding detail, until one precise subtype emerges. Here is how the pieces fit together.
| Layer | What It Examines | What It Tells Doctors |
|---|---|---|
| 1. Morphology | How the cells and the lymph node architecture look under the microscope | First impression of the pattern — for example, whether Reed-Sternberg cells of Hodgkin lymphoma are present |
| 2. Immunophenotyping | Immunohistochemistry & flow cytometry read surface markers (CD20, CD3, CD30, CD15…) | B-cell vs T-cell vs Hodgkin; the "fingerprint" of markers narrows the subtype |
| 3. Molecular / genetic | Cell-of-origin, MYC / BCL2 rearrangements | Refines aggressive B-cell subtypes and flags high-risk "double-hit" patterns |
| 4. Staging tests | PET-CT, blood tests, bone marrow biopsy | How far the disease has spread — combined with the subtype to plan treatment |
The subtype is decided by a haematopathologist on tissue, not by a scan alone. Classification follows the WHO system and NCCN / ESMO guidance. Which exact tests are run depends on the appearance of your biopsy.
A rushed or incomplete workup is one of the commonest reasons a lymphoma is mis-classified. CION coordinates every layer under one roof, so nothing is missed before treatment is chosen.
Wherever possible an excisional (whole-node) biopsy is preferred over a fine-needle sample, because the architecture of the node — not just the cells — is part of the diagnosis. When a whole node cannot be reached, a core needle biopsy is the next best option.
Reading the marker fingerprint with immunohistochemistry and flow cytometry is where B-cell, T-cell and Hodgkin disease are separated. CION arranges these as standard, so your subtype is not left as a best guess.
For aggressive B-cell lymphomas, cell-of-origin and double-hit testing can change the risk category. NCCN and ESMO expect this detail before high-risk cases are finalised, and CION arranges it on your tissue.
Every lymphoma diagnosis is discussed by a multidisciplinary team before a plan is set. If you already have a report, our specialist team offers a free written second opinion to confirm the subtype first.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just been told you have lymphoma, unsure what the subtype on your report means, or want the diagnosis confirmed before therapy? CION's haematology team is here to help.
Everything starts with a tissue sample of good quality. For lymphoma, the architecture of a lymph node is part of the diagnosis, so an excisional biopsy — removing a whole node — is usually preferred to a fine-needle aspiration, which can miss the pattern entirely. Where a whole node is not accessible, a core needle biopsy under image guidance is the next best choice.
Sometimes the enlarged node is first spotted on a scan done for another reason. If it is deep-seated or part of bulky disease, the team plans the safest way to sample it. What matters is getting enough good tissue, because every downstream test — immunophenotyping, molecular studies — depends on it. Read what to expect from the procedure on our lymph node biopsy page.
The haematopathologist first studies the tissue under the microscope — its morphology. This gives the first strong clue: for example, the large Reed-Sternberg cells that point to Hodgkin lymphoma, or the sheets of large cells seen in DLBCL.
Immunohistochemistry stains the tissue for specific proteins on the cells. The pattern of markers is a fingerprint: CD20 points to B-cell disease, CD3 to T-cell disease, and CD30 / CD15 help identify Hodgkin lymphoma. These marker names are testing concepts, not medicines, and are central to how the subtype is called.
Flow cytometry reads the same kind of markers on cells in a fluid sample, quickly and in fine detail. Together, IHC and flow cytometry are what separate B-cell from T-cell lymphomas and confirm Hodgkin disease — the layer that turns "a lymphoma" into a named subtype.
For many aggressive B-cell lymphomas, immunophenotyping is not the end of the story. Molecular and genetic tests add the finishing layer that can change the risk category and, sometimes, the exact subtype.
NCCN and ESMO guidelines expect this molecular information for high-risk cases before treatment is finalised. CION arranges cell-of-origin and rearrangement testing on your tissue so the subtype is complete, not partial.
Once the subtype is named, staging tests map how far the disease has spread. These include a PET-CT, blood tests (which may reveal a high LDH in fast-growing disease), and — for some subtypes — a bone marrow biopsy. When a PET scan is used to check response later, its activity is graded on the Deauville score. A summary of the routine blood work is on our blood tests in lymphoma page.
All of this comes together in your pathology report, which states the full subtype name, the markers found, and (for B-cell disease) the cell-of-origin and any high-risk features. Ask your consultant to explain it in plain words and request a copy. Understanding your subtype is understanding your disease.
Because subtypes behave so differently, so do their outcomes. Published series report that Hodgkin lymphoma has among the highest cure rates in oncology — broadly in the region of 80–90% long-term survival — while diffuse large B-cell lymphoma is often reported around 60–70%, with many patients cured (figures per published series referenced in NCCN and ESMO guidance). Indolent (slow-growing) subtypes may not be curable but are frequently controlled for many years.
These are general, published figures — outcomes vary considerably by individual, depending on stage, age, general health and the specific features of your subtype. They are shared to give context, not a personal prediction. Your own outlook is best discussed with your specialist once your full subtype and stage are known. For regimen names and detailed treatment options, see Lymphoma Treatment in Hyderabad.
NCCN guidelines specifically recommend expert haematopathology review of the biopsy for a suspected lymphoma. Because the named subtype dictates the whole treatment plan, a specialist re-review before therapy begins is one of the most valuable second opinions in cancer care — and can occasionally revise the diagnosis when the initial sample or testing was limited. (Source: NCCN Clinical Practice Guidelines in Oncology, B-cell and Hodgkin Lymphomas.)
A pathology review before treatment is especially worthwhile in a few situations:
CION offers a dedicated free written second-opinion service. Our specialist team re-reviews your report and slides, arranges any missing tests, and confirms the subtype before any therapy is recommended. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma team — especially valuable if immunophenotyping or molecular testing has not yet been done on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Your subtype is decided on tissue, not on a scan or a blood test alone. After an excisional (whole-node) biopsy, a haematopathologist examines how the cells look under the microscope, then runs immunohistochemistry and flow cytometry to read the surface markers on the cells (for example CD20, CD3, CD30). Where needed, molecular and genetic tests add the final layer. These findings are combined against the World Health Organization classification to name one specific subtype. That exact name — not just "lymphoma" — is what drives the whole treatment plan, so the workup is done carefully before therapy begins.
The answer comes from your pathology report, which names the subtype in full — for example classic Hodgkin lymphoma, diffuse large B-cell lymphoma, or a T-cell lymphoma. The report also records the markers found on the cells and, for aggressive B-cell types, the cell-of-origin and any high-risk genetic features. Your consultant will walk you through what the name means, whether it is fast-growing or slow-growing, and what it implies for treatment. If any part is unclear, ask for it in plain language and request a copy — you are entitled to understand your own diagnosis. A treatment plan is only finalised once the subtype is confirmed.
Lymphoma classification is the international system — maintained by the World Health Organization and referenced by NCCN and ESMO — that sorts more than 60 distinct lymphomas into named subtypes based on the cell they come from (B-cell, T-cell or NK-cell), how the cells look, their surface markers and their genetics. It matters because two lymphomas that look similar on a scan can need completely different treatment: some are curable with a short course of therapy, others are slow-growing and monitored, and a few need urgent intensive treatment. Getting the classification right is the single most important step before treatment — the name determines the therapy, the intensity and the likely outlook.
A blood test can raise suspicion — for example a high LDH can suggest a fast-growing lymphoma — and a PET-CT shows where disease is and how active it is. But neither can name the subtype, because that requires looking directly at the architecture and markers of the lymphoma cells. Those come only from a tissue sample. This is why doctors insist on a proper lymph node biopsy rather than relying on imaging. Blood tests and scans are essential for staging and for tracking response, but the diagnosis and subtype are always confirmed on tissue, examined by a haematopathologist and interpreted against the WHO classification.
Several layers of testing are run on the same tissue. First, morphology — how the cells and the node architecture look under the microscope. Then immunohistochemistry and flow cytometry / immunophenotyping read the pattern of surface and internal markers (such as CD20, CD3, CD30, CD15) to tell B-cell from T-cell disease and to spot Hodgkin lymphoma. For aggressive B-cell lymphomas, molecular and genetic tests establish the cell-of-origin and check for high-risk rearrangements (for example MYC, BCL2 — the "double-hit" pattern). A bone marrow biopsy may be added for staging. Together these define one precise subtype.
A morphology and immunohistochemistry result is often available within several days of the biopsy, while flow cytometry and molecular tests can take a little longer. It is normal — and a sign of thoroughness — for the final subtype to be issued only after all the layers are back. Occasionally an initial impression is refined once immunophenotyping or genetics returns; this is why an experienced haematopathology review matters and why a specialist centre is worth choosing. At CION the biopsy, immunophenotyping, molecular testing and staging are coordinated together, and the case is reviewed at a tumour board before treatment is finalised.
Yes — a pathology review before treatment is one of the most valuable second opinions in oncology, and NCCN specifically supports expert haematopathology review for lymphoma. Because the subtype dictates the entire plan, confirming it is well worth the short wait, particularly if testing was limited, if the sample was a needle rather than a whole node, or if the diagnosis was borderline between subtypes. CION offers a free written second opinion: our team re-reviews your pathology report and slides, arranges any missing immunohistochemistry or molecular tests, and confirms the subtype before any therapy is recommended. Request your free second opinion to be sure of the diagnosis.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.